European Society of Cardiology Congress 2024

The ESC Congress took place in London from August 30th to September 2nd, gathering more than 30.000 participants. The spotlight of this year’s congress was Personalising Cardiovascular Care. Four new ESC Clinical Practice Guidelines were released on the management of Atrial Fibrillation, Peripheral and Aortic Diseases, Chronic Coronary Syndromes and Elevated Blood Pressure and Hypertension. The ProCardio Center for Innovation contributed to the scientific program by chairing sessions, participating in debates and presenting results from original scientific studies.

Published 12/4/2024

ProCardio researchers outside the conference venue — ProCardio Center for Innovation were well represented at ESC in London.

Image 1/8

A group of people sitting on a stage with a large screen

ProCardio researchers posing inside the conference venue

Prof Thor Edvardsen chaired the session Clinical Case Management: aortic stenosis and morbid obesity.

Kristoffer Andresen presenting his research in Cardiac Imaging.

Cecilie and Nina infront of a red telephone booth

Bendik presenting his research on Covid-19 vaccine associated myocarditis

Professor Thor Edvardsen chaired the session Clinical Case Management: aortic stenosis and morbid obesity. This session addressed the challenges of correctly diagnosing and optimally treating morbidly obese patients with aortic stenosis. Morbid obesity entails challenges in several aspects regarding the treatment of aortic stenosis patients including diagnostics, comorbidities, procedural planning, operative risk and outcome after valvular replacement.

Kristoffer Andresen presented his work Mechanical wave velocities by clutter filter wave imaging detects myocardial dysfunction in acute coronary syndrome at the moderated ePoster session Imaging in acute coronary syndrome. This work demonstrated the potential of the novel echocardiographic imaging modality of mechanical wave imaging for detecting myocardial dysfunction in patients suffering from acute coronary syndrome.

Bendik Skinningsrud presented his work COVID-19 vaccine associated myocarditis in Norway – a nationwide validation study at the moderated ePoster session Myocarditis: good tools for predicting bad outcomes. In this study investigating all cases of vaccine associated myocarditis in Norway from COVID-19 vaccination in the period from 2020 to 2022, the prevalence of this unexpected adverse event was found to be low and to occur predominantly in young men and women of middle to older age.

Thuy Mi Nguyen presented her work All-cause mortality and incidence of appropriate therapy from a primary preventive implantable defibrillator in patients with non-ischemic dilated cardiomyopathy at the moderated ePoster session Implantable cardioverter defibrillators: maximising protection and quality of life. The study investigates the long-term outcomes and incidence of ICD therapy in patients with non-ischemic dilated cardiomyopathy (niDCM) who received an ICD for primary prevention between 2014 and 2022. The findings indicate that patients implanted with a primary prevention ICD for niDCM after the 2016 DANISH study were, 10 years younger and had higher left ventricular ejection fraction. However, there was no significant reduction in all-cause mortality, nor was there a difference in the occurrence of appropriate ICD therapies.

Image 1/8